FOB Price
Get Latest Price|
- Minimum Order
Country:
China
Model No:
-
FOB Price:
Place of Origin:
-
Price for Minimum Order:
-
Minimum Order Quantity:
-
Packaging Detail:
-
Delivery Time:
-
Supplying Ability:
-
Payment Type:
-
Product Group :
-
China
Contact Person Maggie
Quanzhou, Fujian
Semaglutide, also known as semaglutide, is a GLP*1 receptor
agonist. It is an analog of glucagon-like peptide*1 (GLP*1) and is
commonly used in the study of type 2 diabetes. Developed by Novo
Nordisk, Semaglutide is a potent and long-lasting anti-diabetic
drug that is injected subcutaneously.
Effect:
Semaglutide is a long-acting formulation developed based on the
basic structure of liraglutide, and its effect in treating type 2
diabetes is better. Semaglutide is prepared by solid-liquid phase
synthesis. Solid-phase synthesis method:
Linear peptide Aib8, Arg*4GLP*1 (*-Chemicalbook*7) and fatty side
chain acylating agent, the linear peptide Lys*6 is modified with a
synthetic fatty chain acylating agent under alkaline conditions to
obtain semaglutide, and the homemade sample is tested for
biological activity by time-resolved fluorescence resonance energy
transfer immunoassay.
| Country: | China |
| Model No: | - |
| FOB Price: | Get Latest Price |
| Place of Origin: | - |
| Price for Minimum Order: | - |
| Minimum Order Quantity: | - |
| Packaging Detail: | - |
| Delivery Time: | - |
| Supplying Ability: | - |
| Payment Type: | - |
| Product Group : | - |
